Skip to content Skip to content

Press Releases


Filter Releases
 
INCLINE VILLAGE, Nev., Feb. 7, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 1:00 p.m. ET in New York City. (Logo:  http://phot...
INCLINE VILLAGE, Nev., Feb. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it has retired $10,028,000 aggregate principal amount of the Company's 2.875% Convertible Senior Notes due February 15, 2012 (the Old Notes). Pursuant to ...
INCLINE VILLAGE, Nev., Jan. 24, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid to its stockholders in 2012 will be $0.15 per share of common stock.  The $0.15 dividends will each be paid on March 14, June 14, September 14 and Dec...
INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible...
INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 30th Annual JP Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2012 at 9:30 a.m. Pacific time. (Logo:...
INCLINE VILLAGE, Nev., Jan. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the expiration and preliminary results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Conve...
INCLINE VILLAGE, Nev., Dec. 19, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million, as compared with actual results of $76 million for the fourth quarter of 2010, a five percent decrease. Total anticipated revenue for the year en...
INCLINE VILLAGE, Nev., Dec. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 8, 2011, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF5580...
INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Christine Larson has resigned her position as vice president and chief financial officer of PDL effective as of December 9, 2011.  The company will immediately begin a search for a new CFO. (Logo:  http://photos.prnewswire.com/...
INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of ...
INCLINE VILLAGE, Nev., Dec. 7, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 155.354 shares of common stock per $1,000 principal amount or approximately $6.44 per share, effective Decem...
INCLINE VILLAGE, Nev., Nov. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has commenced an offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2011 Convertible Senio...
INCLINE VILLAGE, Nev., Nov. 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Revenues Total revenues for the third quarter of 2011 were $83.8 million, compared to $86.4 million for...
INCLINE VILLAGE, Nev., Nov. 8, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference next week in New York City.  The presentation will begin at 10 a.m. EST on Tuesday, Nov...
INCLINE VILLAGE, Nev., Nov. 2, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2011, on Wednesday, November 9, 2011, after the markets close. PDL's management will host a conference call and webcast that day at 4:30 p.m...
= add release to Briefcase